Clinical Trial Update: DP13 - A Phase II Study in Patients With Primary Aldosteronism [Phase 2]

View source ↗

Summary

DP13, a drug developed by Damian Pharma AG, completed a Phase II study in patients with primary aldosteronism. Results from the Phase II trial have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aldosteronism

Drugs mentioned

• DP13

Snippet

Sponsor: Damian Pharma AG | Conditions: Primary Aldosteronism | Phase 2 | Status: COMPLETED | Results posted: 2024-11-22